Weill Medical College of Cornell University: Prostatic Neoplasms trials

The registry lists 40 Prostatic Neoplasms studies with Weill Medical College of Cornell University as lead sponsor. 6 are open to participants now and 19 have results posted.

Early Phase 1 1Phase 1 13Phase 2 13No phase 16(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancErRecruitingNCT05948657Not applicable
• Clinical Trial of Approaches to Prostate Cancer SurgeryRecruitingNCT05155501Not applicable
• Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate CancerRecruitingNCT04946370Phase 1/2
• Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate CancerRecruitingNCT04886986Phase 1
• Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate CancerRecruitingNCT04402151Phase 2
• Ablative Therapy in the Management of Prostate CancerRecruitingNCT03492424
• Prostate Cancer - Comparative Outcomes of New Conceptual Paradigms for TreatmentCompletedNCT04890314Results posted
• PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy 2CompletedNCT04815876Not applicableResults posted
• Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)TerminatedNCT04631744Phase 2Results posted
• Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPCActive, not recruitingNCT04506567Phase 1Results posted
• Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 WeeksActive, not recruitingNCT04422132Phase 2Results posted
• PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate CancerCompletedNCT04220983Not applicableResults posted
• PSMA Imaging of Localized Prostate CancerCompletedNCT03675451Phase 2Results posted
• MRI-guided Stereotactic Body Radiotherapy (SBRT) With Simultaneous Integrated Boost for Prostate CancerCompletedNCT03664193Not applicableResults posted
• PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT)Active, not recruitingNCT03663218Not applicableResults posted
• A Prospective, Randomized Trial Comparing Office-based MR-guided Prostate Biopsy ApproachesTerminatedNCT03632655Not applicableResults posted
• 177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPCTerminatedNCT03545165Phase 1/2Results posted
• Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate CancerTerminatedNCT03439033Phase 2Results posted
• Phase I Trial of 225Ac-J591 in Patients With mCRPCCompletedNCT03276572Phase 1Results posted
• Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPCCompletedNCT03042468Phase 1/2Results posted
• Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate CancerTerminatedNCT02911922Not applicableResults posted
• A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate CancerCompletedNCT01799278Phase 2Results posted
• Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate CancerTerminatedNCT01558492Phase 2Results posted
• 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate CancerActive, not recruitingNCT00859781Phase 2Results posted
• Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate CancerCompletedNCT00195039Phase 2Results posted
• ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcerWithdrawnNCT05567770Phase 1
• Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate CancerActive, not recruitingNCT05471414Not applicable
• Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)Active, not recruitingNCT05345444Not applicable
• Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate CancerTerminatedNCT04984343Phase 2
• Re-treatment 225Ac-J591 for mCRPCCompletedNCT04576871Early Phase 1
• A Prospective Trial on Nerve Sparing Techniques Performed in Radical ProstatectomyTerminatedNCT04393831Not applicable
• pCHIP: Prostate Cancer Health Impact ProgramTerminatedNCT04293406
• Effect of Radiotherapy Variables on Circulating Effectors of Immune Response and Local MicrobiomeCompletedNCT03383107
• Neoadjuvant J591 Treatment for Prostate CancerCompletedNCT02693860Phase 1
• J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell CountsCompletedNCT02552394Phase 1
• Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate CancerCompletedNCT00916123Phase 1
• Epidemiologic, Clinical and Genetic Profile of Prostate Cancer in Arab CountriesWithdrawnNCT00801996
• Use of Multiphoton Microscopy in the Diagnosis of CancerCompletedNCT00652210Phase 1
• Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 AntibodyCompletedNCT00538668Phase 1
• Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00003391Phase 1